Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes

Vaccine

Volumn 28, Issue 34, 2010, Pages 5617-5626

  Hanafi, Laïla Aïcha ^a   Bolduc, Marilène ^b   Gagné, Marie Ève Laliberté ^b   Dufour, Florent ^a   Langelier, Yves ^a   Boulassel, Mohammed Rachid ^c   Routy, Jean Pierre ^c,d   Leclerc, Denis ^b   Lapointe, Réjean ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Cross presentation; Potexvirus; Virus like particles

Indexed keywords

CD40 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; CAPSID PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DEATH; CELL EXPANSION; CHIMERA; CONTROLLED STUDY; CROSS PRESENTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALVA MOSAIC VIRUS; MOSAIC VIRUS; POTEXVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LIKE AGENT; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; B LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; PROTEIN ENGINEERING;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, CD40; B-LYMPHOCYTES; CAPSID PROTEINS; CELL PROLIFERATION; CLONING, MOLECULAR; CROSS-PRIMING; EPITOPES; HUMANS; MOLECULAR SEQUENCE DATA; POTEXVIRUS; PROTEIN ENGINEERING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77955056229     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.024     Document Type: Article

References (33)

1. Ada G. Vaccines and vaccination. The New England Journal of Medicine 2001, 345(14):1042-1053.
2. Daar A.S., Martin D.K., Smith A.C., Nast S., Singer P.A. Top ten biotechnologies for improving health in developing countries. Nature Genetics 2002, 32:229-232.
3. Stern A.M., Markel H. The history of vaccines and immunization: familiar patterns. New challenges. Health Affairs 2005, 24(3):611-621.
4. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet 2004, 364:1757-1765.
5. Quan F.-S., Huang C., Compans R.W., Kang S.-M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. Journal of Virology 2007, 81(7):3514-3524.
6. Kumar S., Ochoa W., Singh P., Hsu C., Schneemann A., Manchester M., et al. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology 2009, 388:185-190.
7. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M-e, Koukavica I., Baz M., et al. Development of universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26(27-28):3395-3403.
8. Denis J., Majeau N., Acosta-Ramirez E., Savard C., Bedard M.-C., Simard S., et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007, 363(1):59-68.
9. Marusic C., Vitale A., Pedrazzini E., Donini M., Frigerio L., Bock R., et al. Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study. Transgenic Research 2009, 18(4):499-512.
10. Moròn V.G., Rueda P., Sedlik C., Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. The Journal of Immunology 2003, 171:2242-2250.
11. Ruedl C., Storni T., Lechner F., Bächi T., Bachmann M.F. Cross-presentation of virus-like particles by skin- derived CD8-dendritic cells: a dispensable role for TAP. European Journal of Immunology 2002, 32:818-825.
12. Sedlik C., Dridi A., Deriaud E., Saron M.F., Rueda P., Sarraseca J., et al. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. Journal of Virology 1999, 73(4):2739-2744.
13. Woo W-p, Doan T., Herd K.A., Tindle R.W. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. Journal of Virology 2006, 80(8):3975-3984.
14. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. Journal of Virology 2008, 82(2):785-794.
15. Leclerc D., Beauseigle D., Denis J., Morin H., Pare C., Lamarre A., et al. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. Journal of Virology 2007, 81(3):1319-1326.
16. Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F., et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. Journal of Virology 2001, 75(18):8434-8439.
17. Tremblay M.-H., Majeau N., Gagné M-EL, Lecours K., Morin H., Duvignaud J.-B., et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. The FEBS Journal 2006, 273(1):14-25.
18. Zhang S., Cubas R., Li M., Chen C., Yao Q. Virus-like particle vaccine activates conventional B2 cells and promotes B cell diffrentiation to IgG2a producing plasma cells. Molecular Immunology 2009, 46:1988-2001.
19. Haynes J.R., Dokken L., Wiley J.A., Cawthon A.G., Bigger J., Harmsen A.G., et al. Influenza-pseudotyped Gag virus-like article vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2008, 1-12.
20. Côté F., Paré C., Majeau N., Bolduc M., Leblanc E., Bergeron M.G., et al. Nucleotide sequence and phylogenetic analysis of a new potexvirus: malva mosaic virus. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2008, 8(1):83-93.
21. Laliberté M.E., Lecours K., Gagné S., Leclerc D. The F13 residue is critical for interaction among the coat protein subunits of papaya mosaic virus. FEBS Journal 2008, 275:1474-1484.
22. Lapointe R., Toso J.F., Butts C., Young H.A., Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. European Journal of Immunology 2000, 30:3291-3298.
23. Pelletier S., Tanguay S., Lee S., Gunaratnam L., Arbour N., Lapointe R. TGF-alpha as a candidate tumor antigen for renal cell carcinomas. Cancer Immunology Immunotherapy 2009, 58(8):1207-1217.
24. Baratova L.A., Grebenshchikov N.I., Shishkov A.V., Kashirin I.A., Radavsky J.L., Jarvekulg L., et al. The topography of the surface of potato virus X: tritium planigraphy and immunological analysis. Journal of General Virology 1992, 73:229-235.
25. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. Journal of Clinical Investigation 1997, 100:2757-2765.
26. Lapointe R., Bellemare-Pelletier A., Housseau F., Thibodeau J., Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Research 2003, 63:2836-2843.
27. Ackerman A.L., Cresswell P. Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1. The Journal of Immunology 2003, 170:4178-4188.
28. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annual Review of Immunology 1991, 9:271-296.
29. Barth H., Ulsenheimer A., Pape G.R., Diepolder H.M., Hoffmann M., Thimme R., et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 2005, 105:3605-3614.
30. Yan M., Peng J., Jabbar I.A., Liu X., Filgueira L., Frazer I.H., et al. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 2004, 324:297-310.
31. Adhikary D., Behrends U., Feederle R., Delecluse H-j, Mautner J. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles. Journal of Virology 2008, 82(8):3903-3911.
32. Lehner M., Bailo M., Stachel D., Roesler W., Parolini O., Holter W. Caspase-8 dependent apoptosis induction in malignant myeloid cells by TLR stimulation in the presence of IFN-alpha. Leukemia Research 2007, 31:1729-1735.
33. Wang H.L., Akinci I.O., Baker C.M., Urich D., Bellmeyer A. The intrinsic apoptotic pathway is required for lipopolysaccharide-induced lung endothelial cell death. The Journal of Immunology 2007, 179:1834-1841.